Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tomivosertib · 1 trial · 1 indication
The incidence of TEAEs and SAEs will be summarized and TEAEs will also be summarized by severity and according to their relationship to Tomivosertib (eFT-508).
Defined as the proportion of subjects who achieve a best overall response of complete response (CR) or partial response (PR).
Defined as the interval from the start of Tomivosertib (eFT-508) to the occurrence of PD or death from any cause.
| Arm | Type | Description |
|---|---|---|
| Tomivosertib (eFT-508) | EXPERIMENTAL | Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert. |
| Name | Type | Description |
|---|---|---|
| Tomivosertib (eFT-508) | DRUG | Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2. |
Inclusion Criteria: * Must provide written informed consent and any authorizations required by local law; * Men or women 18 years of age; * Initiated monotherapy with an anti-PD-1 or anti-PD-L1 agent (avelumab, atezolizumab, durvalumab, nivolumab, or pembrolizumab) in accordance with the package in...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Tomivosertib is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 2 clinical development. The drug is being evaluated in combination with PD-1/PD-L1 inhibitor therapy for patients with solid tumors.
Tomivosertib is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The drug is currently in Phase 2 clinical development for the treatment of solid tumors.
Tomivosertib is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of solid tumors, with one completed clinical trial.
Tomivosertib has been studied in one clinical trial with the identifier NCT03616834. This Phase 2 trial evaluated Tomivosertib in combination with PD-1/PD-L1 inhibitor therapy for solid tumors. The trial was completed and enrolled 39 participants in the United States.
Yes, Tomivosertib is also known as eFT-508. In clinical trials, it has been referred to as eFT-508, as seen in the trial title for NCT03616834. The drug is being developed for the treatment of solid tumors.